Market expert Sandip Sabharwal maintains a constructive long-term outlook but stresses selectivity due to near-term risks like rising input costs and competition. He favors midcaps and selective smallcaps, seeing opportunities in consumer durables, while cautioning on financials and quick commerce. Large pharma deals require careful integration and valuation assessment.
Jupiter Wagons Q4 Results: Cons PAT tumbles 72% to Rs 29 crore, revenue falls 25% YoY
Jupiter Wagons saw its net profit drop 72% to Rs 29 crore in the March quarter. Revenue also fell 25% to Rs 780 crore. The
May 30, 2026